Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impaired T-cell response to mRNA vaccination heralds risk of COVID-19 in long-term allogeneic hematopoietic stem cell transplantation survivors.
Einarsdottir S, Waldenström J, Törnell A, Ringlander J, Stenbäck JB, Malmström S, Hellstrand K, Martner A, Lagging M. Einarsdottir S, et al. Among authors: lagging m. Haematologica. 2024 Jan 1;109(1):303-307. doi: 10.3324/haematol.2023.283551. Haematologica. 2024. PMID: 37534518 Free PMC article. No abstract available.
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group. Zeuzem S, et al. Among authors: lagging m. J Hepatol. 2005 Aug;43(2):250-7. doi: 10.1016/j.jhep.2005.05.016. J Hepatol. 2005. PMID: 16082736 Clinical Trial.
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F, Tielemans WC, Zondervan PE, Lagging M, Westin J, Schalm SW. Orlent H, et al. Among authors: lagging m. J Hepatol. 2006 Oct;45(4):539-46. doi: 10.1016/j.jhep.2006.05.015. Epub 2006 Jun 30. J Hepatol. 2006. PMID: 16905220 Clinical Trial.
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Romero AI, et al. Among authors: lagging m. J Infect Dis. 2006 Oct 1;194(7):895-903. doi: 10.1086/507307. Epub 2006 Aug 29. J Infect Dis. 2006. PMID: 16960776 Clinical Trial.
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Among authors: lagging m. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K; DITTO-HCV Study Group. Westin J, et al. Among authors: lagging m. J Viral Hepat. 2007 Jan;14(1):29-35. doi: 10.1111/j.1365-2893.2006.00777.x. J Viral Hepat. 2007. PMID: 17212641 Clinical Trial.
111 results